胃癌患者血清内皮细胞特异性分子-1水平检测及临床意义

目的探究内皮细胞特异性分子-1（ESM-1）在胃癌患者血清中的表达及临床意义以及作为胃癌肿瘤标志物的可行性。方法以酶联免疫吸附测定法（ELISA）检测102例胃癌患者术前血清ESM-1的水平。同时以41例健康成年人血清ESM-1水平为对照。分析以上病例的癌胚抗原（CEA）、CA19-9及CA72-4检验结果及临床病理资料，以ROC曲线分析ESM-1作为胃癌肿瘤标志物的可行性，以生存曲线分析ESM-1与胃癌患者预后的关系。结果相比健康人而言，无新辅助化疗胃癌患者血清中ESM-1的浓度明显升高（1．01±0．68）μg／L比（0．72±0．53）μg／L，P=0．005]。ROC曲线分析得出血清ESM-1诊断胃癌的敏感性为73．9％。特异性为51．2％，其敏感性高于CEA（16．1％）、CA19-9（18．3％）及CA72-4（23．2％）。生存分析显示，高水平ESM-1（大于0．826μg／L）提示预后不良（P〈0．05）。结论ESM-1在胃癌患者外周血中升高，其可作为潜在的血清学标志物用于胃癌的辅助诊断及预后判断。

Detection of serum endothelial cell specific molecule 1 in gastric cancer patients and its clinical significance

Objective To investigate the expression of serum endothelial cell specific molecule 1 （ESM-1） in gastric cancer and to evaluate the effect of serum ESM-1 as a potential serum biomarker. Methods Serum ESM-1 was detected by enzyme-linked immnnosorbent assay （ELISA） and CEA, CA19.9, CA72.4 were detected by electrochemilnminescence immunoassay （ECLIA） in 102 patients with gastric cancer preoperatively. At the same time, serum ESM-1, CEA, CA19-9, CA72-4 in 41 healthy adults volunteers were detected with the same method. In addition, the follow-up data of all the patients were collected. Results Compared to healthy volunteers, the serum ESM-1 level in gastric cancer patients increased （P〈0.01）. The sensitivity and specificity of serum ESM-1 were 73.9% and 51.2% respectively. In contrast, the sensitivities of CEA, CA19-9 and CA72-4 were only 16.1%, 18.3% and 23.2% respectively. High level of serum ESM-1 indicated poor outcomes （P〈0.05）. Conclusions Serum ESM-1 increases in the peripheral blood of the gastric cancer patients. It may be a potential serum marker to help diagnosis and prediction of prognosis of gastric cancer patients.